Supplementary materials

'Ebro Lands' is located in the south-west of Catalonia, in the southern part of
river Ebre, and formed by four regions: Baix Ebre, Montsià, Terra Alta and
Ribera d'Ebre (all into red circle). AFABE study (Baix Ebre, into green circle).
The figure shows the relationship between the subjects in previous study
AFABE and those ones included in the current study.

Figure S1. Current territory study map.

Table S1. Continuous basal variables.

Continuous variables	Units	N	Variable modeling
Following-time	years	8,237	Average following-time years/patient from 01/01/2013 to patient's death or until the end of the study (31/12/2017).
Age	years	8,237	Age (years-old) at the inclusion
Weight	kg	4,708	Weight measures average in following time
BMI[a]	kg/m^2	3,504	BMI measures average in following time
Systolic blood pressure (SBP)	mmHg	6,309	SBP measures average in following time
Diastolic blood pressure (DBP)	mmHg	6,253	DBP measures average in following time
Heart rate (HR)	bpm	5,501	Heart rate measures average in following time
Glycated haemoglobin (HbA1c)	%	5,793	HbA1c measures average in following time
CHA$_2$DS$_2$VASc		8,237	CHA$_2$DS$_2$VASc measures average in following time

[a] Body mass index.

Table S2. Categorical basal variables.

	Units	Variable modeling
Gender		**Registered condition in the medical history**
Diabetes mellitus 2	mg/dL	Basal glycemia > 126 mg/dL twice; glycemia at 2 hours of the TTOG > 200 mg/dL twice; random glycemia > 200 mg/dL and typical symptoms; HbA1c > 6.5% twice.
Insulin		Registered condition in the electronic prescription
Oral antidiabetics		Registered condition in the electronic prescription
Hypertension	mmHg	Blood pressure > 140/90mmHg (three consecutive measures).
Beta-blockers		Registered condition in the electronic prescription
Calcium antagonists		Registered condition in the electronic prescription
ACE inhibitors- ARBs[a]		Registered condition in the electronic prescription
Diuretics		Registered condition in the electronic prescription
Hypercholesterolemia	mg/dL	One total cholesterol > 250mg/dL
Myocardial infarction		Registered condition in the ICD-10
Peripheral vascular disease		Registered condition in the ICD-10
Valvular disease		Registered condition in the ICD-10
Heart failure		Registered condition in the ICD-10
Thromboembolism		Registered condition in the ICD-10
Chronic renal insufficiency	ml/min/1.73 m^2	Glomerular filtration < 60 ml/min/1.73 m^2
Dementia		Registered condition in the ICD-10

Table S3. Multivariable-Adjusted by Sex and Interaction for Atrial Fibrillation Risk Factors in the Overall Sample.

Variable	Interaction	Sex Hazard Ratios		P Value	Relative Risk Ratio (CI95%) (Women/Men)
**Age (years) ($\bar{x}\pm ds$)	< 0.001	Women	1.06 (1.01–1.03)	0.001	0.98 (0.89–1.07)
		Men	1.08 (1.04–1.12)	0.01	
**Weight (kg) ($\bar{x}\pm ds$)	< 0.001	Women	1.01 (0.98–1.03)	0.372	0.99 (0.96–1.02)
		Men	1.02 (1.01–1.04)	0.001	
BMI^d(kg/m^2) ($\bar{x}\pm ds$)	0.522	Women	1.04 (0.97–1.10)	0.276	1.01 (0.95–1.07)
		Men	1.02 (0.97–1.06)	0.611	
**Diastolic blood pressure (mmHg) ($\bar{x}\pm ds$)	0.496	Women	0.99 (0.96–1.03)	0.85	0.95 (0.90–1.0)
		Men	1.04 (0.99–1.04)	0.286	
**Heart rate (bpm)	< 0.001	Women	0.89 (0.69–1.15)	0.191	0.89 (0.64–1.14)
		Men	0.99 (0.97–1.01)	0.444	
HbA1c^e n (%)	0.496	Women	0.89 (0.69–1.15)	0.374	0.96 (0.54–1.02)
		Men	0.92 (0.77–1.11)	0.392	
Peripheral vascular disease n (%)	0.24	Women	1.62 (0.86–48.2.64)	0.152	1.04 (0.79–1.25)
		Men	1.55 (1.08–2.11)	0.075	
Valvular disease n (%)	0.24	Women	0.61 (0.22–1.72)	0.35	0.83 (0.0–2.48)
		Men	0.73 (0.26–2)	0.539	
**CHA$_2$DS$_2$VASc ($\bar{x}\pm ds$)	0.003	Women	3.45 (1.56–7.63)	0.002	2.97 (0.0–6.66)
		Men	1.16 (0.67–1.99)	0.589	
**Oral antidiabetics n (%)	0.35	Women	0.96 (0.52–1.76)	0.893	1.35 (0.29–2.41)
		Men	0.71 (0.40–1.28)	0.258	
**Beta-blockers n (%)	0.349	Women	0.88 (0.50–1.55)	0.644	1.14 (0.3–2.01)
		Men	0.77 (0.49–1.19)	0.232	
**Calcium antagonists n (%)	0.803	Women	0.87 (0.51–1.48)	0.614	0.67 (0.0–1.73)
		Men	1.28 (0.83–2.0)	0.266	
**ACE inhibitors- ARBs^f (%)	0.264	Women	1.40 (0.78–2.49)	0.256	3.04 (1.87–4.21)

		Men	0.46 (0.24–0.89)	0.02	
Diuretics n (%)	0.609	Women	1.31 (0.79–2.19)	0.293	1.77 (0.77–2.77)
		Men	0.74 (0.49–1.10)	0.137	

[a] Angiotensin converting enzyme inhibitors-angiotensin receptor blockers.